A temperature-responsive PLA-based nanosponge as a novel nanoadjuvant and efficient delivery carrier of Ag85B for effective vaccine against Mycobacterium tuberculosis.

IF 8.2 2区 生物学 Q1 CELL BIOLOGY
Jin-Seung Yun, Soo-Min Kim, Jin Sil Lee, Su Hyun Jeong, Hyeryeon Oh, Panmo Son, Sunghyun Kim, Young-Ran Lee, Eunkyung Shin, Sang-Jun Ha, Yong-Woo Jung, Dokeun Kim, Hye-Sook Jeong, Won Il Choi
{"title":"A temperature-responsive PLA-based nanosponge as a novel nanoadjuvant and efficient delivery carrier of Ag85B for effective vaccine against Mycobacterium tuberculosis.","authors":"Jin-Seung Yun, Soo-Min Kim, Jin Sil Lee, Su Hyun Jeong, Hyeryeon Oh, Panmo Son, Sunghyun Kim, Young-Ran Lee, Eunkyung Shin, Sang-Jun Ha, Yong-Woo Jung, Dokeun Kim, Hye-Sook Jeong, Won Il Choi","doi":"10.1186/s12964-025-02105-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis (TB) is a contagious disease and the second leading cause of death worldwide. The Bacille Calmette-Guérin (BCG) vaccine, the only licensed TB vaccine, has insufficient protective efficacy in adults, necessitating the development of new TB vaccines. Ag85B, a protein-subunit TB vaccine, is a promising candidate due to its high immunogenicity. However, its hydrophobicity presents challenges in manufacturing, expression, and purification, and Ag85B alone does not elicit sufficient immune stimulation. To overcome these limitations, this study aimed to design a temperature-responsive amine-terminated polylactic acid (PLA)-based nanosponge (aPNS) as both a nanoadjuvant and an efficient delivery carrier for Ag85B.</p><p><strong>Methods: </strong>Ag85B was produced using an EZtag fusion tag vector, achieving high product yield and purity. It was then loaded into aPNS, a nanoparticle system with a PLA core and Pluronic shell, through a temperature-responsive process at 4 °C that preserved protein bioactivity. The stability and sustained-release profile of Ag85B@aPNS were evaluated. In vitro cytotoxicity and cellular uptake studies were conducted using macrophages. Protective efficacy and immunogenicity were assessed in M. tuberculosis-challenged mice and BCG-primed mice.</p><p><strong>Results: </strong>The Ag85B protein was successfully produced and loaded into aPNS, which exhibited good colloidal stability and a sustained-release profile. Neither the synthesized Ag85B nor the aPNS showed significant cytotoxicity. aPNS enhanced the cellular uptake of antigens by macrophages. Compared to BCG, Ag85B@aPNS demonstrated superior protective efficacy against M. tuberculosis in mice and improved immunogenicity in BCG-primed mice.</p><p><strong>Conclusion: </strong>Ag85B@aPNS is a viable candidate for TB vaccination, showing potential as both a standalone vaccine and a BCG-booster. Its ability to enhance immunogenicity and provide protection highlights its promise in addressing the limitations of current TB vaccines.</p>","PeriodicalId":55268,"journal":{"name":"Cell Communication and Signaling","volume":"23 1","pages":"159"},"PeriodicalIF":8.2000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963517/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Communication and Signaling","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s12964-025-02105-2","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Tuberculosis (TB) is a contagious disease and the second leading cause of death worldwide. The Bacille Calmette-Guérin (BCG) vaccine, the only licensed TB vaccine, has insufficient protective efficacy in adults, necessitating the development of new TB vaccines. Ag85B, a protein-subunit TB vaccine, is a promising candidate due to its high immunogenicity. However, its hydrophobicity presents challenges in manufacturing, expression, and purification, and Ag85B alone does not elicit sufficient immune stimulation. To overcome these limitations, this study aimed to design a temperature-responsive amine-terminated polylactic acid (PLA)-based nanosponge (aPNS) as both a nanoadjuvant and an efficient delivery carrier for Ag85B.

Methods: Ag85B was produced using an EZtag fusion tag vector, achieving high product yield and purity. It was then loaded into aPNS, a nanoparticle system with a PLA core and Pluronic shell, through a temperature-responsive process at 4 °C that preserved protein bioactivity. The stability and sustained-release profile of Ag85B@aPNS were evaluated. In vitro cytotoxicity and cellular uptake studies were conducted using macrophages. Protective efficacy and immunogenicity were assessed in M. tuberculosis-challenged mice and BCG-primed mice.

Results: The Ag85B protein was successfully produced and loaded into aPNS, which exhibited good colloidal stability and a sustained-release profile. Neither the synthesized Ag85B nor the aPNS showed significant cytotoxicity. aPNS enhanced the cellular uptake of antigens by macrophages. Compared to BCG, Ag85B@aPNS demonstrated superior protective efficacy against M. tuberculosis in mice and improved immunogenicity in BCG-primed mice.

Conclusion: Ag85B@aPNS is a viable candidate for TB vaccination, showing potential as both a standalone vaccine and a BCG-booster. Its ability to enhance immunogenicity and provide protection highlights its promise in addressing the limitations of current TB vaccines.

温度响应pla纳米海绵作为新型纳米佐剂和Ag85B高效递送载体用于有效的结核分枝杆菌疫苗。
背景:结核病是一种传染性疾病,是全球第二大死因。卡介苗(Bacille calmette - gusamrin, BCG)是唯一获得许可的结核病疫苗,但它对成人的保护作用不足,因此有必要开发新的结核病疫苗。Ag85B是一种蛋白质亚单位结核疫苗,由于其高免疫原性,是一种很有希望的候选疫苗。然而,它的疏水性在制造、表达和纯化方面存在挑战,而且单独Ag85B不能引起足够的免疫刺激。为了克服这些限制,本研究旨在设计一种温度响应的胺端聚乳酸(PLA)基纳米海绵(aPNS),作为Ag85B的纳米佐剂和有效的递送载体。方法:采用EZtag融合标记载体制备Ag85B,产品收率高,纯度高。然后通过4°C的温度响应过程将其加载到aPNS中,aPNS是一种具有PLA核心和Pluronic外壳的纳米颗粒系统,以保持蛋白质的生物活性。对Ag85B@aPNS的稳定性和缓释特性进行了评价。利用巨噬细胞进行体外细胞毒性和细胞摄取研究。在M. tuberculosis攻毒小鼠和bcg引物小鼠中评估其保护效果和免疫原性。结果:成功制备了Ag85B蛋白并将其装载到aPNS中,该蛋白具有良好的胶体稳定性和缓释特性。合成的Ag85B和aPNS均未表现出明显的细胞毒性。aPNS增强巨噬细胞对抗原的细胞摄取。与卡介苗相比,Ag85B@aPNS在小鼠中对结核分枝杆菌具有更好的保护作用,并且在BCG引物小鼠中具有更好的免疫原性。结论:Ag85B@aPNS是一种可行的结核病疫苗候选疫苗,显示出作为独立疫苗和bcg增强剂的潜力。它增强免疫原性和提供保护的能力突出了它在解决当前结核病疫苗的局限性方面的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.00
自引率
0.00%
发文量
180
期刊介绍: Cell Communication and Signaling (CCS) is a peer-reviewed, open-access scientific journal that focuses on cellular signaling pathways in both normal and pathological conditions. It publishes original research, reviews, and commentaries, welcoming studies that utilize molecular, morphological, biochemical, structural, and cell biology approaches. CCS also encourages interdisciplinary work and innovative models, including in silico, in vitro, and in vivo approaches, to facilitate investigations of cell signaling pathways, networks, and behavior. Starting from January 2019, CCS is proud to announce its affiliation with the International Cell Death Society. The journal now encourages submissions covering all aspects of cell death, including apoptotic and non-apoptotic mechanisms, cell death in model systems, autophagy, clearance of dying cells, and the immunological and pathological consequences of dying cells in the tissue microenvironment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信